Full-Time

Sr. Medical Ambassador / Medical Science Liaison

Msl, Mountain West

Posted on 5/14/2024

Tarsus Pharamceuticals

Tarsus Pharamceuticals

201-500 employees

Develops treatments for eye care diseases

Compensation Overview

$158.2k - $221.6kAnnually

+ Bonus + Stock Equity

Mid, Senior

Denver, CO, USA

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Required Skills
Communications
Requirements
  • Doctorate of optometry, or MD, PharmD, PhD with eye care expertise required.
  • 3+ years of experience as a medical science liaison in eye care is preferred; or 3+ years of clinical experience in eyecare with at least one year of industry experience or 7 + years of clinical practice in eyecare.
  • Strong emotional intelligence and presentation skills.
  • Ability to plan, organize, manage, and prioritize workload proactively in a fast-paced environment.
  • Ability to navigate systems and processes including Microsoft Office and customer relationship management software, work independently, and be self-motivated.
  • Ability to collect actionable insights and critically analyze data.
  • Ability to influence and collaborate with peers.
  • Strong verbal and written communication skills to convey technical and clinical information.
Responsibilities
  • Manage key opinion leader (KOL) optometrists and ophthalmologists in a designated region, ensuring compliant conduct per PhRMA and Tarsus guidelines.
  • Be the primary medical affairs KOL point of contact for day to day needs and peer-based scientific exchange, adhering to our Tarsus scientific platform; engagements may include both virtual and live interactions.
  • Collect actionable insights from field scientific exchange, prioritize and collate these insights to shape medical strategy.
  • Provide whole practice education to optometric and ophthalmic centers.
  • Provide resources to facilitate disease state education in Optometry schools and Ophthalmology residency programs.
  • Instruct customers (upon request) on investigator initiated trial and medical information procedures.
  • Compliantly identify and recommend KOLs for a variety of projects (including advisory boards, medical education initiatives, training, publications, special projects, clinical trials, business development evaluations) based on expertise, interests, and competencies.
  • Plan KOL engagements and schedule and attend scientific sessions at local, regional and national medical meetings as needed.
  • Liaise with local and regional optometric and ophthalmic medical societies.
  • Present scientific evidence to the payer community.
  • Provide leadership and expertise on medical affairs projects and initiatives.
  • Participate in continual optimization of training, insights gathering and field medical processes.
  • Host local disease state scientific exchanges and “lid+lash labs.”
  • Participate in compliant and collaborative engagements with cross-functional team members including training and KOL meetings.
  • Provide clinical trial support as needed and determine by the clinical development team.
  • Manage territory budget, metrics, KOL mapping and CRM entries.
Tarsus Pharamceuticals

Tarsus Pharamceuticals

View

Tarsus Pharmaceuticals develops treatments for diseases that lack effective solutions, focusing mainly on eye care and infectious diseases. Their key product, XDEMVY, is an FDA-approved eye drop solution used to treat Demodex Blepharitis, a condition affecting the eyelids. The company also has a pipeline of potential treatments for other conditions, including Lyme Disease Prevention and Rosacea. Tarsus differentiates itself from competitors by concentrating on specific medical needs and maintaining a strong commitment to ethical practices and compliance. Their goal is to improve patient outcomes by providing effective treatments for conditions that currently have limited options.

Company Size

201-500

Company Stage

IPO

Total Funding

$58.4M

Headquarters

Irvine, California

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • Growing awareness of Demodex blepharitis expands market for Tarsus's XDEMVY.
  • Telemedicine rise offers new marketing opportunities for Tarsus's products.
  • FDA's focus on unmet needs may expedite Tarsus's pipeline approvals.

What critics are saying

  • Increased competition in ophthalmic treatments challenges Tarsus's market position.
  • Potential clinical trial delays could affect Tarsus's product pipeline.
  • Supply chain constraints may hinder XDEMVY's production and distribution.

What makes Tarsus Pharamceuticals unique

  • Tarsus focuses on high unmet needs in ophthalmic and infectious diseases.
  • Their lead product, XDEMVY, is FDA-approved for Demodex blepharitis treatment.
  • Tarsus's pipeline includes innovative treatments for Lyme disease and Rosacea.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Vacation

Hybrid Work Options

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

0%

2 year growth

8%
MarketBeat
Nov 22nd, 2024
Mutual of America Capital Management LLC Invests $4.29 Million in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Mutual of America Capital Management LLC invests $4.29 million in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS).

The Manila Times
Nov 13th, 2024
Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors

Tarsus welcomes Kate Goodrich, M.D., MHS, to its Board of Directors.

Vision Monday
Nov 12th, 2024
Tarsus Pharmaceuticals Appoints Elizabeth Yeu, MD, as Chief Medical Officer

IRVINE, Calif.- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a company that applies proven science and new technology to eyecare to improve treatment for patients, has announced the appointment of Elizabeth Yeu, MD, as chief medical officer, effective November 4, 2024.

Fierce Pharma
Aug 14th, 2024
Tarsus 'firing on all cylinders' as Xdemvy launch, sales force expansion roll ahead: CEO

Meanwhile, Tarsus in April picked up $200 million in financing from Pharmakon Advisors, on top of the $180 million equity offering the company pulled off earlier in the year.

Yahoo Finance
Apr 23rd, 2024
Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon

IRVINE, Calif., April 23, 2024 (GLOBE NEWSWIRE) - Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it has secured $200 million in committed capital from funds associated with Pharmakon Advisors, LP.

INACTIVE